Product	Alternate Name	Type	Strength	Quantity	Price (USD)	Buy Now
	Cozaar	losartan	Generic	50mg	100TAB	$47.00
	Cozaar	losartan	Brand	100mg	30TAB	$80.00
	Cozaar	losartan	Brand	100mg	60TAB	$120.00
	Cozaar	losartan	Brand	100mg	90TAB	$152.00
	Cozaar	losartan	Brand	12.5mg	30TAB	$64.00
	Cozaar	losartan	Brand	12.5mg	90TAB	$100.00
	Cozaar	losartan	Brand	50mg	30TAB	$70.00
	Cozaar	losartan	Brand	50mg	90TAB	$117.00

Offsite Cozaar Blogs

• 2010-03-16 12:29:00
  by Blood Pressure Monitors

  Buy Generic Hyzaar online GENERIC NAME: losartan and hydrochlorothiazide BRAND NAME: Hyzaar DRUG CLASS AND MECHANISM: Hyzaar is a combination of losartan (Cozaar) and hydrochlorothiazide and is used for treating high blood pressure. For more information, please see the information for each of the tw ...

• 2010-03-11 13:20:00
  by A "New" Merck, Reviewed 2010 Edition. . . .

  Oops! — I neglected to mention that on Tuesday, immediately after the “ New Merial” JV announcement, CFO Peter Kellog presented at a Cowen & Co. investor conference. Streaming audio of the CFO’s remarks here; the most important sound-bite? Right here: . . . . 2010 will be a choppy year for the New M ...

• 2010-03-11 13:18:00
  by New Merck, Reviewed

  Oops! — I neglected to mention that on Tuesday, immediately after the “ New Merial” JV announcement, CFO Peter Kellog presented at a Cowen & Co. investor conference. Streaming audio of the CFO’s remarks here; the most important sound-bite? Right here: . . . . 2010 will be a choppy year for the New M ...

• 2010-03-08 22:45:00
  by Intellectual Property Law and Policy

  Teva Pharmaceuticals USA, Inc. v. Sebelius (DC Circuit, March 2, 2010) Synopsis: Under 21 USC 355, an applicant (brand manufacturer) seeking approval from the Food and Drug Administration (FDA) to sell a new drug publicly lists the patents that it believes would be infringed by “bioequivalent” versi ...

• 2010-03-04 07:32:00
  by PharmaFeed

  Rarely do we experience a court ruling that could benefit a Big Pharma and a generics maker at the same time. But as the Wall Street Journal points out, both Teva Pharmaceutical Industries and Merck are likely to cheer an appeals court decision on the blood pressure drugs Cozaar and Hyzaar. The new ...

• 2010-03-03 23:09:00
  by Pharmaweb

  An appeals court granted Teva a 180-day Hatch-Waxman statutory exclusivity to market two of Merck’s antihypertensives, Hyzaar and Cozaar. This decision overturned the July 2009 decision where a district court maintained that Teva had forfeited the exclusivity. The hatch waxman act offers the first o ...

• 2010-03-03 10:29:00
  by New Merck, Reviewed

  Teva is in the driver’s seat, now in the US — as its generic version of Merck’s Cozaar ® blood pressure medicine looks to be approved by the FDA early next month — thus giving it six-months of exclusive sales of the triple blockbuster, in generic form. US consumers will likely see a more than 50 per ...

• 2010-03-01 14:01:00
  by A "New" Merck, Reviewed 2010 Edition. . . .

  This bears repeating: as New Merck wends its way through a series of deals (like the AstraZeneca buy-back of Nexium ® deal announced this morning — bringing in $647 million in April), in the next few months, Cozaar and Hyzaar sales are going to plummet. The deals, are intended to offset, in part, th ...

• 2010-03-01 13:58:00
  by New Merck, Reviewed

  This bears repeating: as New Merck wends its way through a series of deals (like the AstraZeneca buy-back of Nexium ® deal announced this morning — bringing in $647 million in April), in the next few months, Cozaar and Hyzaar sales are going to plummet. The deals, are intended to offset, in part, th ...

• 2010-02-24 18:17:00
  by Commenti a: GRANDE CAPODANNO AL PICCOLO RANCH

  If [u]merck contact number re cozaar[/u] or of the face, or occurs, with trandolapril should immediately, the in with and until the disappears.

• 2010-02-20 22:27:00
  by Healthreason.com

  Antihypertensive combination drug Lotrel (amlodipine/benazepril) was shown to be more effective than benazapril plus diuretics in preventing the development of chronic kidney disease. The new study, Avoiding Cardiovascular Events in Combination therapy in Patients Living with Systolic Hypertension ( ...

• 2010-02-20 06:57:00
  by bharatbook

  Expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and M ...

• 2010-02-18 22:34:00
  by Bashert

  See, it’s funny because Cozaar is an angiotensin II receptor antagonist. And it ends with an”ar” sound.

• 2010-02-18 06:21:00
  by bharatbook

  Following the patent expiries of ARBs Datamonitor expects antihypertensives sales in the seven major markets to record sales of $29.5 billion in 2018, a drop of over $6 billion compared to 2008. With no promising novel pipeline agents, pharmaceutical companies have little choice but to adopt line ex ...

• 2010-02-16 00:53:00
  by Life Behind The Caution Tape

  Okay, so I’ve been on SSRIs for my PMS symptoms for the past 10 years or so, and I’ve been on Lexapro for a majority of those years. For the past year or so I have also been taking 5-HTP to supplement my Lexapro when my PMS has been really bad. For those of you who don’t know, when I am PMSing I get ...